A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
复制标题
DOI：
10.1007/s11060-008-9741-z
复制
发表时间：
2009-03-01
影响因子：
3.9
通讯作者：
Abrey, Lauren E.
中科院分区：
文献类型：
--
作者：
Kreisl, Teri N.;Lassman, Andrew B.;Abrey, Lauren E.
22 名复发性胶质母细胞瘤 (GBM) 患者接受了依维莫司和吉非替尼前瞻性治疗，作为一项更大规模临床试验的一部分，旨在测试哺乳动物雷帕霉素靶点 (mTOR) 和表皮生长因子受体 (EGFR) 的联合抑制作用。主要终点是放射学反应率。次要终点包括无进展生存期以及分子谱与治疗反应的相关性。 36% 的患者病情稳定，14% 出现部分缓解；然而，反应并不持久，只有一名患者在六个月时没有出现进展。传统的反应标准并不能很好地表征放射学变化，并且暗示了肿瘤内治疗的不同效果和/或抗血管生成作用。 EGFR 和 PTEN 状态不能明确预测治疗反应。
Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment.